Pulse Biosciences (PLSE) Net Margin (2021 - 2026)

Pulse Biosciences (PLSE) posted quarterly Net Margin of 34838.37% for Q3 2025, down 559.63% quarter-over-quarter from 5281.51% in Q2 2022.

Pulse Biosciences (PLSE) Net Margin (2021 - 2026) Analysis & Trends

Pulse Biosciences' Net Margin history runs 3 years deep, the most recent figure standing at 34838.37% for Q3 2025.

In Q3 2025, Net Margin changed N/A year-over-year to 34838.37%; the TTM figure through Sep 2025 stood at 25437.21% (changed N/A YoY), while the FY2022 annual figure was 8357.86%, down 381071.0% from the prior year.
Net Margin for Q3 2025 stood at 34838.37%, down from 5281.51% in the prior quarter.
The five-year high for Net Margin was 1872.03% in Q4 2021, with the low at 34838.37% in Q3 2025.
The 3-year median for Net Margin is 3890.32% (2022), against an average of 9696.93%.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Intuitive Surgical	132.71 Bn	127.50 Bn	1.96 Bn	28.46%
2	Becton Dickinson	51.57 Bn	50.71 Bn	2.32 Bn	7.59%
3	Alcon	35.52 Bn	34.17 Bn	1.68 Bn	-
4	Resmed	33.28 Bn	31.81 Bn	861.22 Mn	26.20%
5	Medline	27.86 Bn	25.18 Bn	2.22 Bn	1.81%
6	West Pharmaceutical Services	25.15 Bn	24.71 Bn	329.20 Mn	16.96%
7	Solventum	15.31 Bn	14.91 Bn	1.29 Bn	4.21%
8	Cooper Companies	14.86 Bn	14.72 Bn	735.40 Mn	-7.20%
9	Baxter International	13.63 Bn	11.48 Bn	1.03 Bn	4.26%
10	Pulse Biosciences	3.33 Bn	3.33 Bn	161,000.00	-5,684.79%

Download Data